Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
OncoZenge AB (8LY) Stock Price & Analysis
0 Followers
8LY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.05 - €0.66
Previous Close€0.32
Volume0.00
Average Volume (3M)N/A
Market Cap
€3.70M
Enterprise Value€733.37K
Total Cash (Recent Filing)kr34.47M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding11,713,244
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.05 and its highest was €0.66 in the past 12 months.
What is OncoZenge AB’s market cap?
Currently, no data Available
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Aug 27, 2024 which is in 35 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on May 21, 2024. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 11,713,244 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
---
OncoZenge AB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.60%
12-Months-Change
Fundamentals
Return on Equity
-61.58%
Trailing 12-Months
Asset Growth
-45.47%
Trailing 12-Months
Company Description
OncoZenge AB
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed better pain relief compared with standard therapy. It focuses to implement a phase 3 development program as a basis for regulatory approvals and product launches.
---
Technical Analysis
---